A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis

Methods in Molecular Biology

Volumn 1285, Issue , 2015, Pages 293-315

  Gold, Ben ^a   Warrier, Thulasi ^a   Nathan, Carl ^a  

^a NONE

Author keywords

Acidic pH; Antibiotics; Fatty acids; High throughput screening; Hypoxia; Mycobacterium tuberculosis; Nitric oxide; Non replication; Phenotypic tolerance; Reactive nitrogen species

Indexed keywords

ANTIMYCOBACTERIAL AGENT; FATTY ACID; NITRIC OXIDE; NITRITE; NITROGEN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL SURVIVAL; CARBON SOURCE; HIGH THROUGHPUT SCREENING; HOST; HYPOXIA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH; PRIORITY JOURNAL; STRESS; ANOXIA; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; PHYSIOLOGICAL STRESS; PROCEDURES;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

ANOXIA; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; FATTY ACIDS; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; STRESS, PHYSIOLOGICAL;

EID: 84925236491     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2450-9_18     Document Type: Article

References (46)

1. Nathan C (2012) Fresh approaches to antiinfective therapies. Sci Transl Med 4(140): 140-142. doi: 10.1126/scitranslmed.3003081.
2. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, Cherian J, Rhee K, Ly L, Converse PJ, Ehrt S, Vandal O, Jiang X, Schneider J, Lin G, Nathan C (2008) Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3(3):137–145. doi: 10.1016/j.chom.2008.02.003.
3. Lin G, Li D, de Carvalho LP, Deng H, Tao H, Vogt G, Wu K, Schneider J, Chidawanyika T, Warren JD, Li H, Nathan C (2009) Inhibitors selective for mycobacterial versus human proteasomes. Nature 461(7264):621–626, doi:nature08357[pii]10.1038/nature08357.
4. Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C (2013) N, C-capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets. J Am Chem Soc 135(27):9968–9971. doi: 10.1021/ja400021x.
5. Nathan C, Gold B, Lin G, Stegman M, de Carvalho LP, Vandal O, Venugopal A, Bryk R (2008) A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis 88(Suppl 1):25–33, doi: S1472-9792(08)70034-9[pii]10.1016/S1472-9792(08)70034-9.
6. Loebel RO, Shorr E, Richardson HB (1933) The infl uence of foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 26(2):139–166.
7. Loebel RO, Shorr E, Richardson HB (1933) The infl uence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 26(2):167–200.
8. Nyka W (1974) Studies on the effect of starvation on mycobacteria. Infect Immun 9(5):843–850.
9. Gengenbacher M, Rao SP, Pethe K, Dick T (2010) Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 156(Pt 1):81–87. doi: 10.1099/mic.0.033084-0.
10. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profi ling. Mol Microbiol 43(3):717–731.
11. Xie Z, Siddiqi N, Rubin EJ (2005) Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 49(11):4778–4780. doi: 10.1128/AAC.49.11.4778-4780.2005.
12. Wayne LG, Sramek HA (1994) Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38(9):2054–2058.
13. Wayne LG (1994) Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 13(11):908–914.
14. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64(6):2062–2069.
15. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS (2009) Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918):1215–1218. doi: 10.1126/science.1167498.
16. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE 3rd (2008) Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76(6):2333–2340. doi: 10.1128/IAI.01515-07.
17. Brooks JV, Furney SK, Orme IM (1999) Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 43(5):1285–1288.
18. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE 3rd, Flynn JL (2012) Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 109(35): 14188–14193. doi: 10.1073/pnas.1121497109.
19. Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, Peloquin CA, Orme IM, Basaraba RJ, Lenaerts AJ (2008) Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 52(11):4137–4140. doi: 10.1128/AAC.00196-08.
20. Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N, Lee M, Lee J, Via LE, Lee S, Eum SY, Lee SJ, Goldfeder LC, Cai Y, Jin B, Kim Y, Oh T, Chen RY, Dodd LE, Gu W, Dartois V, Park SK, Kim CT, Barry CE 3rd, Cho SN (2013) Effi cacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57(8):3903–3909. doi: 10.1128/AAC.00753-13.
21. Coates A, Hu Y, Bax R, Page C (2002) The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1(11):895–910. doi: 10.1038/nrd940.
22. Rao SP, Alonso S, Rand L, Dick T, Pethe K (2008) The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 105(33): 11945–11950. doi: 10.1073/pnas.0711697105.
23. Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supek F, Glynne R, Zheng J, Boshoff HI, Barry CE 3rd, Dick T, Pethe K, Camacho LR (2012) A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol 7(7):1190–1197. doi: 10.1021/cb2004884.
24. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG (2007) Low-oxygen- recoveryassay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 51(4):1380–1385, doi:AAC.00055-06[pii]10.1128/AAC.00055-06.
25. MacMicking JD, Taylor GA, McKinney JD (2003) Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302(5645):654–659.
26. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF (1997) Identifi cation of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 94(10):5243–5248.
27. Cunningham-Bussel A, Zhang T, Nathan CF (2013) Nitrite produced by Mycobacterium tuberculosis in human macrophages in physiologic oxygen impacts bacterial ATP consumption and gene expression. Proc Natl Acad Sci U S A 110(45):E4256–E4265. doi: 10.1073/pnas.1316894110.
28. Aly S, Wagner K, Keller C, Malm S, Malzan A, Brandau S, Bange FC, Ehlers S (2006) Oxygen status of lung granulomas in Mycobacterium tuberculosis -infected mice. J Pathol 210(3): 298–305. doi: 10.1002/path.2055.
29. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S (2010) Gluconeogenic carbon fl ow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A 107(21):9819–9824. doi: 10.1073/pnas.1000715107.
30. Munoz-Elias EJ, McKinney JD (2005) Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11(6):638–644, doi:nm1252[pii].10.1038/nm1252.
31. Timm J, Post FA, Bekker LG, Walther GB, Wainwright HC, Manganelli R, Chan WT, Tsenova L, Gold B, Smith I, Kaplan G, McKinney JD (2003) Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A 100(24):14321–14326. doi: 10.1073/pnas.2436197100.
32. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I (2002) ideR, An essential gene in Mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 70(7):3371–3381.
33. Gold B, Rodriguez GM, Marras SA, Pentecost M, Smith I (2001) The Mycobacterium tuberculosis IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. Mol Microbiol 42(3):851–865.
34. Walters SB, Dubnau E, Kolesnikova I, Laval F, Daffe M, Smith I (2006) The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. Mol Micobiol 60(2):312–330. doi: 10.1111/j.1365-2958.2006.05102.x.
35. Hondalus MK, Bardarov S, Russell R, Chan J, Jacobs WR Jr, Bloom BR (2000) Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect Immun 68(5):2888–2898.
36. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, Morris SL, Jacobs WR Jr (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8(10):1171–1174. doi: 10.1038/nm765.
37. Gold B, Deng H, Bryk R, Vargas D, Eliezer D, Roberts J, Jiang X, Nathan C (2008) Identifi cation of a copper-binding metallothionein in pathogenic mycobacteria. Nat Chem Biol 4(10):609–616, doi: nchembio.109[pii].10.1038/nchembio.109.
38. Shi X, Festa RA, Ioerger TR, Butler-Wu S, Sacchettini JC, Darwin KH, Samanovic MI (2014) The copper-responsive RicR regulon contributes to Mycobacterium tuberculosis virulence. mBio 5(1):e00876-13. doi: 10.1128/mBio.00876-13.
39. Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD (2004) Role of KatG catalaseperoxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol 52(5):1291–1302.
40. Shiloh MU, Manzanillo P, Cox JS (2008) Mycobacterium tuberculosis senses host- derived carbon monoxide during macrophage infection. Cell Host Microbe 3(5):323–330. doi: 10.1016/j.chom.2008.03.007.
41. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF (2012) Nonsteroidal anti-infl ammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A 109(40):16004–16011. doi: 10.1073/pnas.1214188109.
42. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, Schoolnik GK (2003) Transcriptional adaptation of Myco bacteriumtuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198(5):693–704. doi: 10.1084/jem.20030846.
43. Zheng P, Somersan-Karakaya S, Lu S, Roberts J, Pingle M, Warrier T, Little D, Guo X, Brickner SJ, Nathan CF, Gold B, Liu G (2014) Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. J Med Chem. doi: 10.1021/jm4019228.
44. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL (1999) Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67(9):4531–4538.
45. McCune RM, Feldmann FM, Lambert HP, McDermott W (1966) Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123(3):445–468.
46. McCune RM, Feldmann FM, McDermott W (1966) Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 123(3):469–486.